Pharmaceuticals Collaboration Deals Report, 2019-2024: Assess Financials Terms, Leading Deals By Value, Most Active Dealmakers, Contract Documents & More
Date
10/2/2024 12:46:02 PM
(MENAFN- GlobeNewsWire - Nasdaq) Dublin, Oct. 02, 2024 (GLOBE NEWSWIRE) -- The "Collaboration Deals in Pharmaceuticals, 2019-2024" report has been added to ResearchAndMarkets.com's offering.
Collaboration Deals in Pharmaceuticals provides a detailed understanding and analysis of how and why companies enter collaboration deals.
Understand deal trends since 2019 Browse collaboration deals Benchmark analysis - identify market value of transactions Financials terms - upfront, milestone, royalties Directory of deals by company A-Z, therapy focus and technology type Leading deals by value Most active dealmakers Identify assets and deal terms for each transaction Access contract documents - insights into deal structures Due diligence - assess suitability of your proposed deal terms for partner companies Save hundreds of hours of research time
Fully revised and updated, the report provides access to collaboration deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of collaboration deals announced since 2019 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual collaboration contract documents as submitted to the Securities Exchange Commission by companies and their partners.
In conclusion, this report provides everything a prospective dealmaker needs to know about collaboration alliances.
Analyzing contract agreements allows due diligence of:
What are the rights granted or optioned? What rights are granted by the agreement? What exclusivity is granted? What is the payment structure for the deal? How are sales and payments audited? What is the deal term? How are the key terms of the agreement defined? How are intellectual property rights handled and owned? Who is responsible for commercialization? Who is responsible for development, supply, and manufacture? How is confidentiality and publication managed? How are disputes resolved? Under what conditions can the deal be terminated? What happens when there is a change of ownership? What subcollaboration and subcontracting provisions have been agreed? Which boilerplate clauses does the company insist upon? Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? Which jurisdiction does the company insist upon for agreement law?
Companies Featured in the Report
2cureX 3B Pharmaceuticals 3D Medicines 3SBio 3T Biosciences 4B Technologies 4C Biomed 4D Pharma 4P-Pharma 7 Hills Pharma 9 Meters Biopharma 22nd Century 23andMe 48Hour Discovery 111 A*STAR Singapore Immunology Network A2 Biotherapeutics Aachen University Abbisko Therapeutics Abbott Laboratories Abbvie AbCellera Biologics Abdul Latif Jameel Health Abilita Bio ABL Bio AbSci ACADIA Pharmaceuticals AC Bioscience Acceleron Pharma Accent Therapeutics Accenture Access to Comprehensive Genomic Profiling Coalition ACEA Therapeutics Acerand Therapeutics Acerta Pharma Acer Therapeutics Ache Actelion Actinium Pharmaceuticals Actuate Therapeutics Acumen Analytics Acumen Pharmaceuticals Adagene Adapsyn Bioscience Adaptimmune Adaptive Biotechnologies Adaptive Phage Therapeutics ADC Therapeutics Addex Therapeutics Adimab and 1,900 more!
For more information about this report visit
About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
CONTACT: CONTACT:
Laura Wood,Senior Press Manager
...
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
MENAFN02102024004107003653ID1108740105
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.